{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:28:39Z","timestamp":1791494919732,"version":"4.3.4"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Educ"],"DOI":"10.1186\/s12909-024-06141-3","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T01:01:54Z","timestamp":1729731714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Expert recommendations for Germany\u2019s integration of psychedelic-assisted therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Sergio R.","family":"Perez Rosal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Birnkammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Chernoloz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monnica T.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-4109","authenticated-orcid":false,"given":"Sonya C.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"7966","key":"6141_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","volume":"618","author":"R Nardou","year":"2023","unstructured":"Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, Wright N, Lama C, Faltin S, Goff LA, Stein-O\u2019Brien GL, D\u00f6len G. Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790\u20138. https:\/\/doi.org\/10.1038\/s41586-023-06204-3.","journal-title":"Nature"},{"issue":"680626","key":"6141_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.680626","volume":"12","author":"M Campbell","year":"2021","unstructured":"Campbell M, Williams MT. The ethic of access: An AIDS activist won public access to experimental therapies, and this must now extend to psychedelics for mental illness. Front Psych. 2021;12(680626):1\u20135. https:\/\/doi.org\/10.3389\/fpsyt.2021.680626.","journal-title":"Front Psych"},{"issue":"18","key":"6141_CR3","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Malievskaia E. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England J Med. 2022;387(18):1637\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2206443.","journal-title":"New England J Med"},{"issue":"Suppl 1","key":"6141_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41386-022-01485-0","volume":"47","author":"M Palfreyman","year":"2022","unstructured":"Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, Reichelt A, Hartsel J, Nivorozhkin A, Inamder A, Varty G. ACNP 61st Annual Meeting: Poster Abstracts P271\u2013P540. Neuropsychopharmacol. 2022;47(Suppl 1):220\u2013370. https:\/\/doi.org\/10.1038\/s41386-022-01485-0.","journal-title":"Neuropsychopharmacol"},{"key":"6141_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11469-023-01149-0","volume":"22","author":"JT La Torre","year":"2024","unstructured":"La Torre JT, Mahammadli M, Faber SC, et al. Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders. Int J Ment Health Addiction. 2024;22:913\u201337. https:\/\/doi.org\/10.1007\/s11469-023-01149-0.","journal-title":"Int J Ment Health Addiction"},{"issue":"4","key":"6141_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","volume":"52","author":"JB Luoma","year":"2020","unstructured":"Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J Psychoactive Drugs. 2020;52(4):289\u201399.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"6141_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759.PMID:35166158;PMCID:PMC8864328","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151\u20138. https:\/\/doi.org\/10.1177\/02698811211073759.PMID:35166158;PMCID:PMC8864328.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"6141_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith KW, Sicignano DJ, Hernandez AV, White CM. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. J Clin Pharmacol. 2022;62(4):463\u201371. https:\/\/doi.org\/10.1002\/jcph.1995.","journal-title":"J Clin Pharmacol"},{"key":"6141_CR9","unstructured":"Lykos Press release 2024: \nhttps:\/\/news.lykospbc.com\/2024-02-09-Lykos-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-MDMA-Assisted-Therapy-for-PTSD."},{"key":"6141_CR10","doi-asserted-by":"publisher","unstructured":"Marks M. Psychedelic Therapy Scrutinized by FDA Advisory Committee? JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.13370. Advance online publication.","DOI":"10.1001\/jama.2024.13370"},{"key":"6141_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00278-024-00710-z","volume":"69","author":"D Repantis","year":"2024","unstructured":"Repantis D, Koslowski M, Fink SB. Ethische Aspekte der Therapie mit Psychedelika. Psychotherapie. 2024;69:115\u201321. https:\/\/doi.org\/10.1007\/s00278-024-00710-z.","journal-title":"Psychotherapie"},{"key":"6141_CR12","doi-asserted-by":"crossref","unstructured":"Beringer K (1927). Der Mescalinrausch: seine Geschichte und Erscheinungsweise.","DOI":"10.1007\/978-3-662-11451-3"},{"issue":"5","key":"6141_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/13634615221129116","volume":"59","author":"P Friesen","year":"2022","unstructured":"Friesen P. Psychosis and psychedelics: historical entanglements and contemporary contrasts. Transcult Psychiatry. 2022;59(5):592\u2013609. https:\/\/doi.org\/10.1177\/13634615221129116.","journal-title":"Transcult Psychiatry"},{"key":"6141_CR14","unstructured":"Hofmann A (1980). LSD, my problem child (J. Ott, Trans.). McGraw-Hill. OR German version is Mein Sorgenkind."},{"key":"6141_CR15","doi-asserted-by":"crossref","unstructured":"Dyck, E. (2008). Psychedelic psychiatry: LSD from clinic to campus. Johns Hopkins University Press.","DOI":"10.1353\/book.3470"},{"issue":"6","key":"6141_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00005053-195812000-00006","volume":"127","author":"BG Eisner","year":"1958","unstructured":"Eisner BG, Cohen S. Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis. 1958;127(6):528\u201339.","journal-title":"J Nerv Ment Dis"},{"key":"6141_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-3643-3","volume-title":"Guided affective imagery with children and adolescents","author":"H Leuner","year":"1983","unstructured":"Leuner H, Horn G, Klessmann E, Klemperer I, Lachman E, Singer JL. Guided affective imagery with children and adolescents. New York: Plenum press; 1983."},{"key":"6141_CR18","volume-title":"Psycholytic therapy: The Research, Conception and Practice of Hanscarl Leuner","author":"T Passie","year":"2023","unstructured":"Passie T, Schlichting M, Bolle R. Psycholytic therapy: The Research, Conception and Practice of Hanscarl Leuner. Santa Fe, NM: Synergetic Press; 2023."},{"key":"6141_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","volume":"142","author":"JJ Rucker","year":"2018","unstructured":"Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200\u201318.","journal-title":"Neuropharmacology"},{"key":"6141_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s10198-020-01184-x","volume":"21","author":"T Bothe","year":"2020","unstructured":"Bothe T, Jacob J, Kr\u00f6ger C, Walker J. How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data. Eur J Health Econ. 2020;21:917\u201330.","journal-title":"Eur J Health Econ"},{"key":"6141_CR21","volume-title":"S3-Leitlinie Posttraumatische Belastungsst\u00f6rung","year":"2019","unstructured":"Sch\u00e4fer I, Gast U, Hofmann A, Knaevelsrud C, Lampe A, Liebermann P, W\u00f6ller W, editors. S3-Leitlinie Posttraumatische Belastungsst\u00f6rung. Berlin: Springer; 2019."},{"key":"6141_CR22","unstructured":"Federal Statistical Office (Destatis). (2020). Gesundheitsausgaben nach Diagnose (ICD-10). Retrieved from \nhttps:\/\/www.rki.de\/DE\/Content\/Gesundheitsmonitoring\/Gesundheitsberichterstattung\/GBEDownloadsT\/depression.html?nn=2370692."},{"key":"6141_CR23","unstructured":"Robert Koch Institute (RKI). (2010). Depression: Factsheet on health reporting. Retrieved from \nhttps:\/\/www.rki.de\/DE\/Content\/Gesundheitsmonitoring\/Gesundheitsberichterstattung\/GBEDownloadsT\/depression.pdf?__blob=publicationFile."},{"issue":"3","key":"6141_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1017\/S0033291716002774","volume":"47","author":"K Kamenov","year":"2017","unstructured":"Kamenov K, Twomey C, Cabello M, Prina AM, Ayuso-Mateos JL. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol Med. 2017;47(3):414\u201325. https:\/\/doi.org\/10.1017\/S0033291716002774.","journal-title":"Psychol Med"},{"issue":"7","key":"6141_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006303","volume":"6","author":"TH Hoppen","year":"2021","unstructured":"Hoppen TH, Priebe S, Vetter I, Morina N. Global burden of post-traumatic stress disorder and major depression in countries affected by war between 1989 and 2019: a systematic review and meta-analysis. BMJ Glob Health. 2021;6(7): e006303.","journal-title":"BMJ Glob Health"},{"issue":"05","key":"6141_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/s-0030-1248510","volume":"37","author":"HH K\u00f6nig","year":"2010","unstructured":"K\u00f6nig HH, Luppa M, Riedel-Heller S. Die Kosten der Depression und die Wirtschaftlichkeit ihrer Behandlung. Psychiatr Prax. 2010;37(05):213\u20135. https:\/\/doi.org\/10.1055\/s-0030-1248510.","journal-title":"Psychiatr Prax"},{"key":"6141_CR27","unstructured":"RWI \u2013 Rheinisch-Westf\u00e4lisches Institut f\u00fcr Wirtschaftsforschung (2011). Depression: Wie die Krankheit unsere Seele belastet. Rheinisch-Westf\u00e4lisches Institut f\u00fcr Wirtschaftsforschung im Auftrag der Allianz Versicherung."},{"issue":"46","key":"6141_CR28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3238\/arztebl.m2022.0314","volume":"119","author":"M Porst","year":"2022","unstructured":"Porst M, von der Lippe E, Leddin J, Anton A, Wengler A, Breitkreuz J, Rommel A. The Burden of Disease in Germany at the National and Regional Level: Results in Terms of Disability-adjusted Life Years (DALY) from the BURDEN 2020 Study. Deutsches \u00c4rzteblatt Int. 2022;119(46):785. https:\/\/doi.org\/10.3238\/arztebl.m2022.0314.","journal-title":"Deutsches \u00c4rzteblatt Int"},{"issue":"8","key":"6141_CR29","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1038\/s41380-022-01661-0","volume":"28","author":"J Moncrieff","year":"2023","unstructured":"Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243\u201356. https:\/\/doi.org\/10.1038\/s41380-022-01661-0.","journal-title":"Mol Psychiatry"},{"key":"6141_CR30","doi-asserted-by":"publisher","unstructured":"Blankart K, Naci H, Chandra A. Availability of new medicines in the US and Germanyfrom 2004 to 2018. JAMA Netw Open. 2002;5(8). https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.29231.","DOI":"10.1001\/jamanetworkopen.2022.29231"},{"key":"6141_CR31","doi-asserted-by":"crossref","unstructured":"Zimmermann C (2011). Der gemeinsame Bundesausschuss: Normsetzung durch Richtlinien sowie Integration neuer Untersuchungs-und Behandlungsmethoden in den Leistungskatalog der GKV (Vol. 8). Springer-Verlag.","DOI":"10.1007\/978-3-642-22752-3"},{"key":"6141_CR32","unstructured":"Marini AM, K\u00f6ster G & Steger A (2021). G-BA bewertet neuen Wirkstoff gegen Depression f\u00fcr akute Kurzzeitbehandlung positiv. Pressemitteilung. \nhttps:\/\/www.g-ba.de\/presse\/pressemitteilungen-meldungen\/973\/."},{"issue":"07","key":"6141_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1055\/s-0030-1261879","volume":"73","author":"B Zschorlich","year":"2011","unstructured":"Zschorlich B, Knelangen M, Bastian H. Die Entwicklung von Gesundheitsinformationen unter Beteiligung von B\u00fcrgerinnen und B\u00fcrgern am Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Das Gesundheitswesen. 2011;73(07):423\u20139.","journal-title":"Das Gesundheitswesen"},{"issue":"1","key":"6141_CR34","doi-asserted-by":"publisher","first-page":"1840123","DOI":"10.1080\/20008198.2020.1840123","volume":"11","author":"CM Monson","year":"2020","unstructured":"Monson CM, Wagner AC, Mithoefer AT, Liebman RE, Feduccia AA, Jerome L, Mithoefer MC. MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. Eur J Psychotraumatol. 2020;11(1):1840123.","journal-title":"Eur J Psychotraumatol"},{"issue":"6","key":"6141_CR35","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00213-022-06083-y","volume":"239","author":"A Sarparast","year":"2022","unstructured":"Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022;239(6):1945\u201376.","journal-title":"Psychopharmacology"},{"issue":"4","key":"6141_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1176\/appi.focus.16407","volume":"16","author":"A Tajika","year":"2018","unstructured":"Tajika A, Ioannidis JPA, Geddes JR. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American Psychiatric Publishing). 2018;16(4):420\u20139. https:\/\/doi.org\/10.1176\/appi.focus.16407.","journal-title":"Focus (American Psychiatric Publishing)"},{"key":"6141_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10879-017-9379-2","volume":"48","author":"SB Thal","year":"2018","unstructured":"Thal SB, Lommen MJ. Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder. J Contemp Psychother. 2018;48:99\u2013108.","journal-title":"J Contemp Psychother"},{"key":"6141_CR38","doi-asserted-by":"crossref","unstructured":"Evans-Brown M, Hughes B, & Sedefov R (2022). Legal classification and international systems for monitoring and responding to novel psychoactive substances. In Novel Psychoactive Substances (pp. 3\u201356). Academic Press.","DOI":"10.1016\/B978-0-12-818788-3.00016-4"},{"issue":"1","key":"6141_CR39","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1021\/acsomega.1c05520","volume":"7","author":"JB Nair","year":"2022","unstructured":"Nair JB, Hakes L, Yazar-Klosinski B, Paisner K. Fully validated, multi-kilogram cGMP synthesis of MDMA. ACS Omega. 2022;7(1):900\u20137. https:\/\/doi.org\/10.1021\/acsomega.1c05520.","journal-title":"ACS Omega"},{"issue":"1","key":"6141_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/can.2018.0030","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Kight R. Regulatory Status of Cannabidiol in the United States: A Perspective. Cannabis and cannabinoid research. 2018;3(1):190\u20134. https:\/\/doi.org\/10.1089\/can.2018.0030.","journal-title":"Cannabis and cannabinoid research"},{"issue":"7969","key":"6141_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/d41586-023-02093-8","volume":"619","author":"R Haridy","year":"2023","unstructured":"Haridy R. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature. 2023;619(7969):227\u20138. https:\/\/doi.org\/10.1038\/d41586-023-02093-8.","journal-title":"Nature"},{"key":"6141_CR42","unstructured":"Thirstrup S (2024). Second chance for psychedelics at the European Medicines Agency. LinkedIn. \nhttps:\/\/www.linkedin.com\/pulse\/second-chance-psychedelics-european-medicines-agency\/."},{"key":"6141_CR43","unstructured":"Haberkamp M (2024, April 16). European regulatory perspective on psychedelic drugs in psychiatry. Eur Med Agency. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-european-regulatory-perspective-psychedelic-drugs-psychiatry-m-haberkamp_en.pdf."},{"key":"6141_CR44","unstructured":"Netherlands 2024 State Commission on MDMA, The Hague, Ministry of Health, Welfare and Sport, Parnassusplein 5, The Hague 2511 VX, The Netherlands; \nhttps:\/\/www.government.nl\/documents\/reports\/2024\/05\/31\/mdma-beyond-ecstasy."},{"issue":"1","key":"6141_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00350-023-6649-8","volume":"42","author":"JC Bublitz","year":"2024","unstructured":"Bublitz JC. Zur strafrechtlichen lage von therapien mit psychedelika. Medizinrecht. 2024;42(1):26\u201332. https:\/\/doi.org\/10.1007\/s00350-023-6649-8.","journal-title":"Medizinrecht"},{"key":"6141_CR46","doi-asserted-by":"publisher","unstructured":"Spangemacher M, Valentino F\u00e4rber L, K\u00e4rtner L, Brand M, Julia Mertens L, Scharf D, Gr\u00fcnder G (2023). Psychedelika in Psychiatrie und Psychotherapie-Trend oder Therapie? Zwischen wirksamer Selbsterfahrung und m\u00f6glicher Destabilisierung. DNP\u2013Die Neurologie Psychiatrie, 24(6);30\u201335. \nhttps:\/\/doi.org\/10.1007\/s15202-023-5803-5.","DOI":"10.1007\/s15202-023-5803-5"},{"key":"6141_CR47","doi-asserted-by":"publisher","unstructured":"Herwig U, Mertens L, Rosal SP, Koller G, Jungaberle A, Borgwardt S, & Gr\u00fcnder G (2023). Psychedelika in der Psychiatrie\u2013Entwicklungen und die Stellung in Deutschland. Fortschritte der Neurologie\u00b7 Psychiatrie, 91(07\/08);311\u2013318. \nhttps:\/\/doi.org\/10.1055\/a-1981-3152.","DOI":"10.1055\/a-1981-3152"},{"key":"6141_CR48","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.nsa.2022.100104","volume":"1","author":"LJ Mertens","year":"2022","unstructured":"Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Gr\u00fcnder G. Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)\u2013Rationale and study design. Neuroscience Appl. 2022;1:100104.","journal-title":"Neuroscience Appl"},{"key":"6141_CR49","doi-asserted-by":"publisher","unstructured":"Evens R, & Wolff M (2024). Die Rolle der Psychotherapie in klinischen Studien mit Psychedelika. Die Psychotherapie, 1\u20137. \nhttps:\/\/doi.org\/10.1007\/s00278-024-00715-8.","DOI":"10.1007\/s00278-024-00715-8"},{"key":"6141_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-016-1163-4","volume":"17","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-M\u00f8ller K, Gluud C. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. 2017;17:1\u201328.","journal-title":"BMC Psychiatry"},{"key":"6141_CR51","doi-asserted-by":"crossref","unstructured":"Kirsch I (2014). The emperor\u2019s new drugs: medication and placebo in the treatment of depression. Placebo, 291\u2013303.","DOI":"10.1007\/978-3-662-44519-8_16"},{"issue":"10","key":"6141_CR52","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","volume":"74","author":"C Locher","year":"2017","unstructured":"Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, Kessler RC, Kossowsky J. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis. JAMA Psychiat. 2017;74(10):1011\u201320. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.2432.","journal-title":"JAMA Psychiat"},{"issue":"10","key":"6141_CR53","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"Mitchell JM, Ot'alora GM, van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., Yazar-Klosinski, B., & MAPP2 Study Collaborator Group","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., Yazar-Klosinski, B., & MAPP2 Study Collaborator Group. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Med. 2023;29(10):2473\u201380. https:\/\/doi.org\/10.1038\/s41591-023-02565-4.","journal-title":"Nature Med"},{"key":"6141_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jad.2023.02.064","volume":"329","author":"JE Verhoeven","year":"2023","unstructured":"Verhoeven JE, Han LKM, Lever-van Milligen BA, Hu MX, R\u00e9v\u00e9sz D, Hoogendoorn AW, Batelaan NM, van Schaik DJF, van Balkom AJLM, van Oppen P, Penninx BWJH. Antidepressants or running therapy: Comparing effects on mental and physical health in patients with depression and anxiety disorders. J Affect Disord. 2023;329:19\u201329. https:\/\/doi.org\/10.1016\/j.jad.2023.02.064.","journal-title":"J Affect Disord"},{"key":"6141_CR55","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/AOG.0000000000000447","volume":"124","author":"JT Andersen","year":"2014","unstructured":"Andersen JT, Andersen NL, Horwitz H, Poulsen HE, Jimenez-Solem E. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet Gynecol. 2014;124:655\u201361. https:\/\/doi.org\/10.1097\/AOG.0000000000000447.","journal-title":"Obstet Gynecol"},{"key":"6141_CR56","unstructured":"FDA. (2023). Psychedelic drugs: Considerations for clinical investigations guidance for industry draft guidance. \nhttps:\/\/www.fda.gov\/media\/169694\/download."},{"key":"6141_CR57","doi-asserted-by":"publisher","unstructured":"Altmann U, Zimmermann A, Kirchmann HA, Kramer D, Fembacher A, Bruckmayer E, Pfaffinger I, von Heymann F, Auch E, Steyer R, & Strauss BM (2016). Outpatient psychotherapy reduces health-care costs: A study of 22,294 insurants over 5 years. Frontiers in Psychiatry, 7(98). \nhttps:\/\/doi.org\/10.3389\/fpsyt.2016.00098.","DOI":"10.3389\/fpsyt.2016.00098"},{"key":"6141_CR58","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/7854_2022_366","volume":"56","author":"AJ Khan","year":"2022","unstructured":"Khan AJ, Bradley E, O\u2019Donovan A, Woolley J. Psilocybin for trauma-related disorders. Curr Top Behav Neurosci. 2022;56:319\u201332. https:\/\/doi.org\/10.1007\/7854_2022_366.","journal-title":"Curr Top Behav Neurosci"},{"issue":"4","key":"6141_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.32872\/cpe.v1i4.34304","volume":"1","author":"N Melcop","year":"2019","unstructured":"Melcop N, von Werder T, Sarubin N, Benecke A. The role of psychotherapy in the German Health Care System. Clin Psychol Eur. 2019;1(4):1\u201312. https:\/\/doi.org\/10.32872\/cpe.v1i4.34304.","journal-title":"Clin Psychol Eur"},{"key":"6141_CR60","unstructured":"Sundmacher L, Schang L, Sch\u00fcttig W, Flemming R, Frank-Tewaag J, & Geiger I, Brechtel T (2018). Gutachten zur Weiterentwicklung der Bedarfsplanung i.S.d. \u00a7\u00a7 99 ff. SGB V zur Sicherung der vertrags\u00e4rztlichen Versorgung. \nhttps:\/\/www.g-ba.de\/downloads\/39-261-3493\/2018-09-20_Endbericht-Gutachten-Weiterentwickklung-Bedarfsplanung.pdf."},{"issue":"2","key":"6141_CR61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/13642530902927352","volume":"11","author":"B Strau\u00df","year":"2009","unstructured":"Strau\u00df B. Patterns of psychotherapeutic practice and professionalisation in Germany. Eur J PsychotherCounsel. 2009;11(2):141\u201350. https:\/\/doi.org\/10.1080\/13642530902927352.","journal-title":"Eur J PsychotherCounsel"},{"key":"6141_CR62","volume-title":"Internationale Klassifikation psychischer St\u00f6rungen: ICD-10, Kapitel V (F, klinisch-diagnostische Leitlinien)","year":"1991","unstructured":"Dilling H, Mombour W, Schmidt MH, editors. Internationale Klassifikation psychischer St\u00f6rungen: ICD-10, Kapitel V (F, klinisch-diagnostische Leitlinien). G\u00f6ttingen, Germany: Hogrefe; 1991."},{"key":"6141_CR63","unstructured":"Wittmann WW, Lutz W, Steffanowski A, Kriz D, Glahn EM, V\u00f6lkle MC, Ruprecht T (2011). Qualit\u00e4tsmonitoring in der ambulanten Psychotherapie: Modellprojekt der Techniker Krankenkasse\u2013Abschlussbericht. Hamburg: Techniker Krankenkasse."},{"issue":"5","key":"6141_CR64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5771\/1611-5821-2015-5-20","volume":"69","author":"T Kopetsch","year":"2015","unstructured":"Kopetsch T, John S, Gibis B, Sch\u00f6pe P. Die Neukonzeption der Bedarfsplanung auf der Basis des GKV-Versorgungsstrukturgesetzes. Gesundheits-und Sozialpolitik. 2015;69(5):20\u20136.","journal-title":"Gesundheits-und Sozialpolitik"},{"key":"6141_CR65","unstructured":"Bundespsychotherapeutenkammer. (2021). BPtK-Newsletter 03\/2021. \nhttps:\/\/api.bptk.de\/uploads\/B_Pt_K_Newsletter_03_2021_e389390c2c.pdf."},{"key":"6141_CR66","unstructured":"Bundespsychotherapeutenkammer. (2023). Weiterentwicklung der psychotherapeutischen Versorgung: Hintergrundpapier. \nhttps:\/\/api.bptk.de\/uploads\/20230713_bptk_hintergrundpapier_weiterentwicklung_psychotherapeutischen_versorgung_d38b567ee6.pdf."},{"key":"6141_CR67","unstructured":"Berger M (2023). Ketamin: Ein psychoaktives Arzneimittel. Nachtschatten Verlag."},{"issue":"4","key":"6141_CR68","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcad.12429","volume":"100","author":"BG Hearn","year":"2022","unstructured":"Hearn BG, Brubaker MD, Richardson G. Counselors\u2019 attitudes toward psychedelics and their use in therapy. J Couns Dev. 2022;100(4):364\u201373.","journal-title":"J Couns Dev"},{"key":"6141_CR69","doi-asserted-by":"publisher","first-page":"743599","DOI":"10.3389\/fpsyt.2021.743599","volume":"12","author":"LA Paige","year":"2021","unstructured":"Paige LA, Rehman A, Syed H, Forcer K, Campbell G. The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Front Psych. 2021;12:743599.","journal-title":"Front Psych"},{"key":"6141_CR70","doi-asserted-by":"crossref","unstructured":"Wells A, Fernandes M, & Reynolds L (2024). Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review. J Psychedelic Studies.","DOI":"10.1556\/2054.2023.00294"},{"key":"6141_CR71","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/wps.20269","volume":"14","author":"CA Zarate Jr","year":"2015","unstructured":"Zarate CA Jr, Niciu MJ. 2015 ketamine for depression: evidence, challenges and promise. World Psychiatry. 2015;14:348\u201350. https:\/\/doi.org\/10.1002\/wps.20269.","journal-title":"World Psychiatry"},{"key":"6141_CR72","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","volume":"142","author":"I Ivan Ezquerra-Romano","year":"2018","unstructured":"Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology. 2018;142:72\u201382. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.017.","journal-title":"Neuropharmacology"},{"issue":"10","key":"6141_CR73","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1177\/0269881117705089","volume":"31","author":"P Glue","year":"2017","unstructured":"Glue P, Medlicott NJ, Harland S, Neehoff S, Anderson-Fahey B, Le Nedelec M, Gray A, McNaughton N. Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of psychopharmacology (Oxford, England). 2017;31(10):1302\u20135. https:\/\/doi.org\/10.1177\/0269881117705089.","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"key":"6141_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2022.113804","volume":"424","author":"WA Jumaili","year":"2022","unstructured":"Jumaili WA, Trivedi C, Chao T, Kubosumi A, Jain S. The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. Behav Brain Res. 2022;424: 113804. https:\/\/doi.org\/10.1016\/j.bbr.2022.113804.","journal-title":"Behav Brain Res"},{"issue":"3","key":"6141_CR75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nwh.2020.03.004","volume":"24","author":"HC Fantasia","year":"2020","unstructured":"Fantasia HC. Esketamine Nasal Spray for Treatment-Resistant Depression. Nurs Womens Health. 2020;24(3):228\u201332. https:\/\/doi.org\/10.1016\/j.nwh.2020.03.004.","journal-title":"Nurs Womens Health"},{"issue":"19","key":"6141_CR76","doi-asserted-by":"publisher","first-page":"11450","DOI":"10.3390\/ijms231911450","volume":"23","author":"D Psiuk","year":"2022","unstructured":"Psiuk D, Nowak EM, Dycha N, \u0141opusza\u0144ska U, Kurzepa J, Samardakiewicz M. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Int J Mol Sci. 2022;23(19):11450. https:\/\/doi.org\/10.3390\/ijms231911450.","journal-title":"Int J Mol Sci"},{"key":"6141_CR77","doi-asserted-by":"publisher","unstructured":"Erritzoe D, Barba T, Greenway KT, Murphy R, Martell J, Giribaldi B, Timmermann C, Murphy-Beiner A, Baker Jones M, Nutt D, Weiss B, & Carhart-Harris R (2024). Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: Observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.\u00a0EClinicalMedicine,\u00a0102799.\u00a0\nhttps:\/\/doi.org\/10.1016\/j.eclinm.2024.102799.","DOI":"10.1016\/j.eclinm.2024.102799"},{"key":"6141_CR78","doi-asserted-by":"publisher","first-page":"1209419","DOI":"10.3389\/fpsyt.2024.1209419","volume":"15","author":"P Wolfson","year":"2024","unstructured":"Wolfson P, Vaid G. Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach. Front Psych. 2024;15:1209419. https:\/\/doi.org\/10.3389\/fpsyt.2024.1209419.","journal-title":"Front Psych"},{"key":"6141_CR79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/a-1298-4546","volume":"54","author":"G Gr\u00fcnder","year":"2021","unstructured":"Gr\u00fcnder G, Jungaberle H. Die m\u00f6gliche Rolle psychedelischer Substanzen in der psychiatrischen Versorgung der Zukunft. Pharmacopsychiatry. 2021;54:191\u20139.","journal-title":"Pharmacopsychiatry"},{"key":"6141_CR80","unstructured":"Gasser P (2012). LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study (study protocol) Vol. 2012. www.maps.org\/research\/lsd\/swisslsd\/LDA1010707.pdf."},{"key":"6141_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (\u00b13,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol. 2013;27:40\u201352.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6141_CR82","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00278-024-00708-7","volume":"69","author":"HD Aicher","year":"2024","unstructured":"Aicher HD, Gasser P. Weiterbildung in psychedelika-assistierter therapie\u2013Erfahrungen aus der Schweiz. Die Psychotherapie. 2024;69(2):107\u201314. https:\/\/doi.org\/10.1007\/s00278-024-00708-7.","journal-title":"Die Psychotherapie"},{"issue":"5","key":"6141_CR83","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0022167817711304","volume":"57","author":"J Phelps","year":"2017","unstructured":"Phelps J. Developing guidelines and competencies for the training of psychedelic therapists. J Humanist Psychol. 2017;57(5):450\u201387. https:\/\/doi.org\/10.1177\/0022167817711304.","journal-title":"J Humanist Psychol"},{"key":"6141_CR84","unstructured":"Mithoefer MC (2015). A manual for MDMA assisted psychotherapy in the treatment of posttraumatic stress disorder. Version 7.Multidisciplinary Association for Psychedelic Studies. \nhttps:\/\/maps.org\/research-archive\/mdma\/MDMA-Assisted-Psychotherapy-Treatment-Manual-Version7-19Aug15-FINAL.pdf."},{"issue":"3","key":"6141_CR85","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1037\/cap0000285","volume":"63","author":"J Rochester","year":"2022","unstructured":"Rochester J, Vallely A, Grof P, Williams M, Chang H, Caldwell K. Entheogens and psychedelics in Canada: Proposal for a new paradigm. Can Psychol. 2022;63(3):413\u201330. https:\/\/doi.org\/10.1037\/cap0000285.","journal-title":"Can Psychol"},{"issue":"4","key":"6141_CR86","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/10508619.2023.2216628","volume":"33","author":"A Bartlett","year":"2023","unstructured":"Bartlett A, Vallely A, Williams MT, Nepton A, Feng R. Building psychedelic studies as an interdisciplinary academic field: Its urgency and its challenges. International Journal for the Psychology of Religion. 2023;33(4):415\u201324. https:\/\/doi.org\/10.1080\/10508619.2023.2216628.","journal-title":"International Journal for the Psychology of Religion"},{"key":"6141_CR87","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0054","author":"M Earleywine","year":"2024","unstructured":"Earleywine M, Gomez SG. Is personal experience essential for effective psychedelic therapists?: The challenges of small, accumulating therapist effects. Psychedelic Medicine. 2024. https:\/\/doi.org\/10.1089\/psymed.2023.0054.","journal-title":"Psychedelic Medicine"},{"key":"6141_CR88","doi-asserted-by":"publisher","DOI":"10.1037\/0000399-000","volume-title":"Deliberate Practice in Psychedelic-Assisted Therapy","author":"S Dames","year":"2024","unstructured":"Dames S, Penn A, Williams M, Zamaria J, Vaz A, Rousmaniere T. Deliberate Practice in Psychedelic-Assisted Therapy. Washington DC: American Psychological Association; 2024. 978-1-4338-4171-2."},{"key":"6141_CR89","unstructured":"MWBO-2018. (2018). \nhttps:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/BAEK\/Themen\/Aus-Fort-Weiterbildung\/Weiterbildung\/20230629_MWBO-2018.pdf."},{"key":"6141_CR90","unstructured":"Br\u00fcckert, C. (2019). BAMF Brief Analysis, Issue 01\/2019 of the Brief Analysis by the Migration, Integration and Asylum Research Centre at the Federal Office for Migration and Refugees, 1\/2019, Second wave of the IAB-BAMF-SOEP Survey. \nhttps:\/\/www.bamf.de\/SharedDocs\/Anlagen\/EN\/Forschung\/Kurzanalysen\/kurzanalyse1-2019-fortschritte-sprache-beschaeftigung.pdf?__blob=publicationFile&v=11."},{"key":"6141_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-019-8060-y","volume":"19","author":"Y Nesterko","year":"2019","unstructured":"Nesterko Y, Friedrich M, Br\u00e4hler E, Hinz A, Glaesmer H. Mental health among immigrants in Germany\u2013the impact of self-attribution and attribution by others as an immigrant. BMC Public Health. 2019;19:1\u20138. https:\/\/doi.org\/10.1186\/s12889-019-8060-y.","journal-title":"BMC Public Health"},{"key":"6141_CR92","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000325","volume":"29","author":"Y Nesterko","year":"2019","unstructured":"Nesterko Y, J\u00e4ckle D, Friedrich M, Holzapfel L, Glaesmer H. Prevalence of post-traumatic stress disorder, depression and somatisation in recently arrived refugees in Germany: an epidemiological study. Epidemiology and psychiatric sciences. 2019;29: e40. https:\/\/doi.org\/10.1017\/S2045796019000325.","journal-title":"Epidemiology and psychiatric sciences"},{"key":"6141_CR93","unstructured":"Aikins MA, Bremberger T, Aikins JK, Gyamerah D, Y\u0131ld\u0131r\u0131m-Caliman D (2021). Afrozensus 2020: Perspektiven, anti-Schwarze rassismuserfahrungen und engagement Schwarzer, afrikanischer und afrodiasporischer menschen in Deutschland, Berlin. \nhttps:\/\/afrozensus.de\/reports\/2020\/Afrozensus-2020-Einzelseiten.pdf."},{"key":"6141_CR94","doi-asserted-by":"publisher","unstructured":"Ball E, Steffens MC, & Niedlich C (2022). Racism in Europe: Characteristics and intersections with other social categories. Frontiers in Psychology, 13(789661). https:\/\/doi.org\/10.3389\/fpsyg.2022.789661","DOI":"10.3389\/fpsyg.2022.789661"},{"key":"6141_CR95","doi-asserted-by":"publisher","unstructured":"Rebstock L (2019). Perspective Matters: Racism and Resistance in the Everyday Lives of Youths of Color in Germany. Who Can Speak and Who Is Heard\/Hurt?: Facing Problems of Race, Racism, and Ethnic Diversity in the Humanities in Germany, 69. \nhttps:\/\/doi.org\/10.1515\/9783839441039-004.","DOI":"10.1515\/9783839441039-004"},{"issue":"e19","key":"6141_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1754470X22000162","volume":"15","author":"M Williams","year":"2022","unstructured":"Williams M, Faber SC, Duniya C. Being an anti-racist clinician. The Cognitive Behaviour Therapist. 2022;15(e19):1\u201322. https:\/\/doi.org\/10.1017\/S1754470X22000162.","journal-title":"The Cognitive Behaviour Therapist"},{"key":"6141_CR97","unstructured":"The Federal Government. (2017). National action plan against racism: Positions and measures to address ideologies of inequality and related discrimination. Germany, Author. \nhttps:\/\/www.bmi.bund.de\/SharedDocs\/downloads\/EN\/publikationen\/2018\/nap-en.pdf;jsessionid=D644D6A2FDC369B08D9CAC46D5C76D25.live891?__blob=publicationFile&v=6."},{"key":"6141_CR98","volume-title":"A Clinician\u2019s Guide to Healing the Wounds of Racial Trauma: A 12-Session CBT-Based Protocol","author":"MT Williams","year":"2024","unstructured":"Williams MT. A Clinician\u2019s Guide to Healing the Wounds of Racial Trauma: A 12-Session CBT-Based Protocol. Wisconsin: PESI Publishing; 2024. ISBN: 978-1683737841."},{"issue":"4","key":"6141_CR99","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cbpra.2022.07.001","volume":"30","author":"MT Williams","year":"2023","unstructured":"Williams MT, Holmes S, Zare M, Haeny AH, Faber SC. An evidence-based approach for treating stress and trauma due to racism. Cogn Behav Pract. 2023;30(4):565\u201388. https:\/\/doi.org\/10.1016\/j.cbpra.2022.07.001.","journal-title":"Cogn Behav Pract"},{"issue":"3","key":"6141_CR100","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1556\/2054.2020.00137","volume":"4","author":"MT Williams","year":"2020","unstructured":"Williams MT, Reed S, George J. Culture and psychedelic psychotherapy: Ethnic and racial themes from three Black women therapists. Journal of Psychedelic Studies. 2020;4(3):125\u201338. https:\/\/doi.org\/10.1556\/2054.2020.00137.","journal-title":"Journal of Psychedelic Studies"},{"key":"6141_CR101","unstructured":"The Ministry of Health of Ukraine. The impact of war on mental health is enormous, Viktor Liashko. Government portal. https:\/\/www.kmu.gov.ua\/news\/vpliv-vijni-na-psihichne-zdorovya-kolosalnij-viktor-lyashko. Accessed 16 Apr 2023."},{"key":"6141_CR102","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13033-023-00598-3","volume":"17","author":"V Seleznova","year":"2023","unstructured":"Seleznova V, Pinchuk I, Feldman I, et al. The battle for mental well-being in Ukraine: mental health crisis and economic aspects of mental health services in wartime. Int J Ment Health Syst. 2023;17:28. https:\/\/doi.org\/10.1186\/s13033-023-00598-3.","journal-title":"Int J Ment Health Syst"},{"key":"6141_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.978703.PMID:36186881;PMCID:PMC9524230","volume":"13","author":"ICZ Lim","year":"2022","unstructured":"Lim ICZ, Tam WW, Chudzicka-Czupa\u0142a A, McIntyre RS, Teopiz KM, Ho RC, Ho CS. Prevalence of depression, anxiety and post-traumatic stress in war-and conflict-afflicted areas: A meta-analysis. Front Psych. 2022;13: 978703. https:\/\/doi.org\/10.3389\/fpsyt.2022.978703.PMID:36186881;PMCID:PMC9524230.","journal-title":"Front Psych"},{"issue":"10","key":"6141_CR104","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00103-020-03215-7","volume":"63","author":"A Hollederer","year":"2020","unstructured":"Hollederer A. Die Gew\u00e4hrleistung von Krankheitshilfen bei asylsuchenden Menschen: Zweiklassenmedizin in Deutschland? [Guarantee of illness assistance for people seeking asylum: Two-tiered medical system in Germany?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63(10):1203\u201318. https:\/\/doi.org\/10.1007\/s00103-020-03215-7.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"}],"container-title":["BMC Medical Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12909-024-06141-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12909-024-06141-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12909-024-06141-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T01:02:48Z","timestamp":1729731768000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmededuc.biomedcentral.com\/articles\/10.1186\/s12909-024-06141-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1186\/s12909-024-06141-3","relation":{},"ISSN":["1472-6920"],"issn-type":[{"value":"1472-6920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Sonya Faber is employed by Angelini Pharma and is a partner in the company Bioville GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The other authors declare no conflicts of interest.This paper contains no clinical trial and no need for ethics consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1202"}}